4th June 2022 | Pharma Updates

PharmaState Updates – Latest Pharma Happenings

Former USFDA officers hired by Indian pharma companies to tide over compliance issues

Lupin has assigned Diana Amador-Toro as senior vice-president, the company announced in an exchange notification. This is not the first time an Indian company has hired a former drug regulator.

Aurobindo Pharma impacted by near-term growth issues and cost pressures

Aurobindo Pharma delivered a weaker-than expected performance in the March quarter, hampered by a poor showing in the US and EU markets, as well as cost pressures and earnings estimates were reduced by up to 15%.

As per PM Modi, India has everything it needs to be a reliable partner

PM Narendra Modi laid the foundation stone for 1,406 projects worth over Rs 80,000 crore in sectors such as agriculture, pharmaceuticals, information technology and electronics, manufacturing, renewable energy, tourism, defence and aerospace, handloom and textiles.

C2i Genomics & Karkinos Healthcare collaborate to bring AI-powered cancer detection & monitoring to India

C2i Genomics, a cancer intelligence company, announced today a strategic partnership with Karkinos Healthcare, a technology-led cancer managed care platform, to co-develop the minimal residual disease (MRD) market in India.

Bristol Myers adds to its Roche rivalry with $4.1 billion Turning Point acquisition

Bristol Myers Squibb is acquiring Turning Point Therapeutics for $4.1 billion in order to compete with Roche and to launch a new cancer asset next year.

FDA raised concerns about heart problems associated with Novavax vaccine

There were four cases of myocarditis, a type of heart inflammation also associated with mRNA vaccines, detected within 20 days of vaccination in the company’s nearly 30,000 patient trial, which was conducted between December 2020 and September 2021.

FDA's response to the baby formula recall reviewed by federal investigators

Federal investigators have launched an investigation into whether FDA properly inspected Abbott Laboratories’ Michigan plant and how the agency oversaw the baby formula recall that resulted in severe shortages.